Attached files

file filename
EX-32.1 - EX-32.1 - CytomX Therapeutics, Inc.ctmx-ex321_13.htm
EX-31.2 - EX-31.2 - CytomX Therapeutics, Inc.ctmx-ex312_7.htm
EX-31.1 - EX-31.1 - CytomX Therapeutics, Inc.ctmx-ex311_9.htm
EX-23.1 - EX-23.1 - CytomX Therapeutics, Inc.ctmx-ex231_11.htm
10-K - 10-K - CytomX Therapeutics, Inc.ctmx-10k_20171231.htm

Exhibit 23.2

CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-214418 and 333-216567) and Form S-8 (Nos. 333-207694, 333-209992 and 333-215795) of CytomX Therapeutics, Inc. of our report dated March 2, 2017 relating to the financial statements, which appears in this Form 10‑K.

 

/s/ PricewaterhouseCoopers LLP

San Jose, California

March 7, 2018